ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
ProQR announced upcoming conference presentations covering its AX-0810 Phase 1 data and next-generation AX-0811 program at TIDES Europe, AASLD The Liver Meeting 2026, and Nature's RNA at the Bench and Bedside V. The AASLD presentations include a late-breaking poster with proof-of-concept evidence of in vivo Axiomer RNA editing of NTCP from the AX-0810 Phase 1 trial, which is being developed for cholestatic disease.
Key figures
- Drug Name
- AX-0810 / AX-0811
- Phase Of Trial
- Phase 1
- Ax0811 initial data timing
- early January 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.